Krishnan A P, Karunamuni R, Leyden K M, Seibert T M, Delfanti R L, Kuperman J M, Bartsch H, Elbe P, Srikant A, Dale A M, Kesari S, Piccioni D E, Hattangadi-Gluth J A, Farid N, McDonald C R, White N S
From the Multimodal Imaging Laboratory (A.P.K., K.M.L., T.M.S., J.M.K., H.B., P.E., A.S., A.M.D., N.F., C.R.M., N.S.W.).
Departments of Radiation Medicine (R.K., T.M.S., J.A.H.-G., C.R.M.).
AJNR Am J Neuroradiol. 2017 May;38(5):882-889. doi: 10.3174/ajnr.A5099. Epub 2017 Mar 9.
ADC as a marker of tumor cellularity has been promising for evaluating the response to therapy in patients with glioblastoma but does not successfully stratify patients according to outcomes, especially in the upfront setting. Here we investigate whether restriction spectrum imaging, an advanced diffusion imaging model, performed after an operation but before radiation therapy, could improve risk stratification in patients with newly diagnosed glioblastoma relative to ADC.
Pre-radiation therapy diffusion-weighted and structural imaging of 40 patients with glioblastoma were examined retrospectively. Restriction spectrum imaging and ADC-based hypercellularity volume fraction (restriction spectrum imaging-FLAIR volume fraction, restriction spectrum imaging-contrast-enhanced volume fraction, ADC-FLAIR volume fraction, ADC-contrast-enhanced volume fraction) and intensities (restriction spectrum imaging-FLAIR 90th percentile, restriction spectrum imaging-contrast-enhanced 90th percentile, ADC-FLAIR 10th percentile, ADC-contrast-enhanced 10th percentile) within the contrast-enhanced and FLAIR hyperintensity VOIs were calculated. The association of diffusion imaging metrics, contrast-enhanced volume, and FLAIR hyperintensity volume with progression-free survival and overall survival was evaluated by using Cox proportional hazards models.
Among the diffusion metrics, restriction spectrum imaging-FLAIR volume fraction was the strongest prognostic metric of progression-free survival ( = .036) and overall survival ( = .007) in a multivariate Cox proportional hazards analysis, with higher values indicating earlier progression and shorter survival. Restriction spectrum imaging-FLAIR 90th percentile was also associated with overall survival ( = .043), with higher intensities, indicating shorter survival. None of the ADC metrics were associated with progression-free survival/overall survival. Contrast-enhanced volume exhibited a trend toward significance for overall survival ( = .063).
Restriction spectrum imaging-derived cellularity in FLAIR hyperintensity regions may be a more robust prognostic marker than ADC and conventional imaging for early progression and poorer survival in patients with glioblastoma. However, future studies with larger samples are needed to explore its predictive ability.
表观扩散系数(ADC)作为肿瘤细胞密度的标志物,在评估胶质母细胞瘤患者的治疗反应方面前景广阔,但未能成功根据预后对患者进行分层,尤其是在初始治疗阶段。在此,我们研究在手术后但放疗前进行的限制性谱成像(一种先进的扩散成像模型)相对于ADC,是否能改善新诊断胶质母细胞瘤患者的风险分层。
回顾性分析40例胶质母细胞瘤患者放疗前的扩散加权成像和结构成像。计算增强扫描和液体衰减反转恢复序列(FLAIR)高信号感兴趣区内的限制性谱成像、基于ADC的高细胞密度体积分数(限制性谱成像-FLAIR体积分数、限制性谱成像-增强扫描体积分数、ADC-FLAIR体积分数、ADC-增强扫描体积分数)以及强度(限制性谱成像-FLAIR第90百分位数、限制性谱成像-增强扫描第90百分位数、ADC-FLAIR第10百分位数、ADC-增强扫描第10百分位数)。采用Cox比例风险模型评估扩散成像指标、增强扫描体积和FLAIR高信号体积与无进展生存期和总生存期的相关性。
在扩散指标中,多因素Cox比例风险分析显示,限制性谱成像-FLAIR体积分数是无进展生存期(P = .036)和总生存期(P = .007)最强的预后指标,其值越高表明进展越早、生存期越短。限制性谱成像-FLAIR第90百分位数也与总生存期相关(P = .043),强度越高表明生存期越短。ADC指标均与无进展生存期/总生存期无关。增强扫描体积在总生存期方面显示出显著趋势(P = .063)。
FLAIR高信号区域的限制性谱成像得出的细胞密度,对于胶质母细胞瘤患者早期进展和较差生存期而言,可能是比ADC和传统成像更可靠的预后标志物。然而,需要未来更大样本量的研究来探索其预测能力。